Overview

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.

Phase:

Phase 2

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Genomic Health®, Inc.
Pfizer

Treatments:

Estrogens
Goserelin
Letrozole
Palbociclib